CliffBio
small molecule

PRISTIQ

DESVENLAFAXINE SUCCINATE

Loss of exclusivityJuly 2027latest FDA-listed patent expiry
CompanyPF PRISM CV

Drug detail

Brand namePRISTIQ
Active ingredientDESVENLAFAXINE SUCCINATE
StrengthEQ 50MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2008
Marketing statusRX

Listed patents

PatentExpiresType
8269040July 2027substance

More from PF PRISM CV

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PRISTIQ patent cliff — loss of exclusivity July 2027 | CliffBio